The cellular redox environment alters antigen presentation by Trujillo, Jonathan A. et al.
    Redox modulated antigen presentation 
1 
 
The cellular redox environment alters antigen presentation* 
 
Jonathan A. Trujillo1,2¶, Nathan P. Croft3,4¶, Nadine L. Dudek3,4¶, Rudragouda Channappanavar1, Alex 
Theodossis4, Andrew I. Webb3, Michelle A. Dunstone4, Patricia T. Illing3, Noah S. Butler1,6, Craig Fett1, 
David C. Tscharke5, Jamie Rossjohn4,7,8, Stanley Perlman1,2 & Anthony W. Purcell3,4,† 
 
1 Department of Microbiology and 2 Interdisciplinary Program in Immunology, University of Iowa, Iowa 
City, Iowa 
3 Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology 
Institute, University of Melbourne, Parkville, Victoria, Australia 
4 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, 
Australia. 
5 Research School of Biology, Australian National University, Canberra, ACT, 0200, Australia 
6 Current address: Department of Microbiology and Immunology, University of Oklahoma Health 
Sciences Center, Oklahoma City, Oklahoma 
7ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Vic 3800, 
Australia. 
8Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF14 
4XN, UK 
 
¶ JAT, NPC and NLD contributed equally to this work. 
Running Title: Redox modulated antigen presentation 
†Joint senior and corresponding authors: Stanley Perlman and Anthony W. Purcell. 
Address all correspondence to Anthony Purcell, Ph.D., Tele: 61-3-9902 9265; Fax: 61-3-9902 9500; 
Email: anthony.purcell@monash.edu or Stanley Perlman, M.D., Ph.D., Tele:319-335-8549; FAX: 319-
335-9006, Email: Stanley-perlman@uiowa.edu 
Keywords: Animal viruses, coronaviruses, antigen presentation, immunology, T cell biology, viral 
immunology, glutathionylation, structural biology 
 
Capsule:  
Background: Modification of cysteine residues, 
including glutathionylation, commonly occurs in 
peptides bound to and presented by MHC 
molecules. 
Results: Glutathionylation of a coronavirus-
specific T cell epitope results in diminished CD8 T 
cell recognition. 
Conclusion: Cysteine modification of a T cell 
epitope negatively impacts the host immune 
response. 
Significance: Cross-talk between virus-induced 
oxidative stress and the T cell response likely 
occurs, diminishing host cell recognition of 
infected cells. 
Summary 
Cysteine-containing peptides represent an 
important class of T cell epitopes, yet their 
prevalence remains underestimated. We have 
established and interrogated a database of 
around 70,000 naturally processed MHC bound 
peptides and demonstrate that cysteine-
containing peptides are presented on the 
surface of cells in an MHC allomorph 
dependent manner and comprise on average 5-
10% of the immunopeptidome. A significant 
proportion of these peptides are oxidatively 
modified, most commonly through covalent 
linkage with the antioxidant glutathione. Unlike 
some of the previously reported Cysteine-based 
modifications, this represents a true 
physiological alteration of cysteine residues. 
Furthermore, our results suggest that 
alterations in the cellular redox state induced 
by viral infection are communicated to the 
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immune system through the presentation of S-
glutathionylated viral peptides, resulting in 
altered T cell recognition. Our data provide a 
structural basis for how the glutathione 
modification alters recognition by virus-specific 
T cells. Collectively, these results suggest that 
oxidative stress represents a mechanism for 
modulating the virus-specific T cell response.  
 
Introduction 
Small fragments of proteins (peptides) derived 
from both intracellular and extracellular sources 
are displayed on the surface of cells by molecules 
encoded within the major histocompatibility 
complex (MHC7). These peptides are recognized 
by T lymphocytes and provide the immune system 
with a surveillance mechanism for the detection of 
pathogens and cancer cells. The fidelity with 
which antigen presentation communicates changes 
in the intracellular proteome is critical for immune 
surveillance. Not only do antigens expressed at 
vastly different abundances need to be represented 
within the array of peptides selected and presented 
at the cell surface (collectively termed the 
immunopeptidome (1,2)), changes in their post-
translational state also need to be conveyed within 
this complex mixture of peptides. For example, 
changes in antigen phosphorylation have been 
linked to cancer and the presentation of 
phosphorylated peptides has been shown to 
communicate the cancerous state of cells to the 
immune system (3-6). Other types of post-
translational modification  (PTM) play a central 
role in the pathogenesis of autoimmune 
diseases(7); such as arginine citrullination in 
arthritis (8-10), deamidation of glutamine residues 
in wheat proteins in coeliac disease (11-15) and 
cysteine oxidation in type 1 diabetes(16,17). 
Cysteine is predicted to be present in up to 14% of 
potential T cell epitopes based on its prevalence in 
various pathogen and host proteomes (18). 
However, reports of cysteine-containing epitopes 
are much less frequent due to technical difficulties 
associated with synthesis and handling of cysteine-
containing peptides and their subsequent 
avoidance in many epitope mapping studies (19). 
Cysteine can be modified in numerous ways 
including cysteinylation (the disulfide linkage of 
free cysteine to peptide or protein cysteine 
residues), oxidation to cysteine sulfenic 
(oxidation), sulfinic (dioxidation) and sulfonic 
acids (trioxidation), S-nitrosylation and S-
glutathionylation. Such modifications may occur 
prior to or during antigen processing; however, the 
role of cysteine-modification in T-cell mediated 
immunity has not been systematically addressed. 
In addition to constitutive presentation of a subset 
of oxidatively modified peptides it is anticipated 
that changes in the proportion of these ligands will 
occur upon infection, since oxidative stress, 
triggering of the unfolded protein response and 
modulation of host cell synthesis by the virus are 
hallmarks of this process (20-27). For example, 
host cell stress responses modulate expression, 
localization and function of Toll-like receptors, a 
key event in the initiation of the immune response 
(28). Oxidative stress would also be predicted to 
affect protein function through PTM of amino 
acids such as cysteine. Indeed, because of the 
reactive nature of cysteine and the requirements 
for cells to regulate the redox state of proteins to 
maintain function, a number of scavenging 
systems for redox reactive intermediates exist. The 
tripeptide glutathione (GSH) is one of the key 
intracellular anti-oxidants, acting as a scavenger 
for reactive oxygen species (ROS). Reduced GSH 
is equilibrated with its oxidised form, GSSG, with 
normal cytosolic conditions being that of the 
reduced state in a ratio of ~50:1 (GSH:GSSG) 
(29). Modification of proteins and peptides with 
GSH (termed S-glutathionylation) occurs 
following reaction of GSSG with the thiol group 
of cysteine in a reaction catalysed by the 
detoxifying enzyme, glutathione S-transferase  
(GST). A variety of cellular processes and 
signalling pathways such as the induction of innate 
immunity, apoptosis, redox homeostasis and 
cytokine production are modulated by this GST-
catalysed PTM (30-32). S-glutathionylation can 
eventuate via oxidative stress, whereby the 
intracellular levels of GSSG increase.  
Given that viruses are known to induce oxidative 
stress (33-35), the intracellular environment of 
viral infection may lead to an increase in S-
glutathionylated cellular proteins and viral 
antigens. For instance, HSV infection induces an 
early burst of ROS, resulting in S-
glutathionylation of TRAF family members, which 
in turn is linked to downstream signalling and 
interferon production (36). The potential for 
modification of viral antigens subsequent to ROS 
production is highlighted by S-glutathionylation of 
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several retroviral proteases leading to host 
modulation of protease function (37). Indeed large 
scale changes in protein S-glutathionylation are 
observed in HIV-infected T cell blasts (38), 
suggesting functional  modulation of both host and 
viral proteins occur via this mechanism. Whether 
these S-glutathionylated proteins inhibit or 
enhance immune responses to the unmodified 
epitope or generate novel T-cell epitopes that are 
subsequently recognised by the adaptive immune 
system is unclear. 
Here, we investigate the frequency of modification 
of cysteine-containing MHC-bound peptides by 
interrogating a large database of naturally 
processed self-peptides derived from B-
lymphoblastoid cells, murine tissues and cytokine-
treated cells. In addition, the functional 
consequences of Cys-modification of T cell 
epitopes was investigated using an established 
model of infection that involves an 
immunodominant cysteine-containing epitope 
derived from a neurotropic strain of mouse 
hepatitis virus, strain JHM (JHMV) (39-41). We 
describe S-glutathionylation of this viral T cell 
epitope and the functional and structural 
implications of redox-modulated antigen 
presentation.  Collectively our studies suggest that 
S-glutathionylation plays a key, previously 




Six-eight week old pathogen-free C57BL/6 (B6) 
mice were purchased (National Cancer Institute, 
Frederick, MD, USA). NOD mice were purchased 
and housed in the Bio21 Institute animal facility 
(Melbourne, Australia). Studies were carried out in 
accordance with accepted standards of humane 
animal care and were approved by the animal 
ethics committee, University of Melbourne. 
Tissues were snap-frozen in liquid nitrogen and 
stored at −80°C. 
Viruses 
Wild-type JHMV was propagated and titered as 
previously described (42). VACV-S510 was 
engineered as previously described (40). Mice 
were infected intraperitoneally with 2x107 PFU of 
VACV-S510 and CD8+ T cell responses measured 
in the spleen. 
Glutathione levels in naïve and JHMV infected 
brain tissue 
Brains were harvested from either naïve mice or 
mice infected intranasally with JHMV at day 7 p.i. 
Brains were directly homogenized into 5% (w/v) 
5-sulfosalicylic acid (SSA). The soluble fraction 
was used for thiol analysis. Total GSH (GSH + 
GSSG) and GSSG were determined using a 
spectrophotometric recycling assay as previously 
described (43,44). Glutathione measurements were 
normalized to the total amount of precipitated 
tissue protein in the SSA-treated samples as 
determined using a bicinchoninic acid protein 
assay with a Micro BCA protein assay reagent kit  
(Pierce Biotechnology, Rockford, IL).  
Staining with H-2Db/S510 and H-2Db/GSH-S510 
tetramer 
Tetramers were obtained either from the 
University of Melbourne Tetramer Facility  
(Parkville, Australia) or the National Institute of 
Allergy and Infectious Diseases MHC Tetramer 
Core Facility (Atlanta, GA). Cells were stained 
with CD8, CD16/CD32 and tetramer and analyzed 
as previously described (45). 
H-2Db binding assay 
Binding assays were performed as described 
previously (46,47). Briefly, RMA-S cells grown to 
a density of 106 cells/ml were incubated at 26˚C 
for 20 h in order to allow stabilisation of “empty” 
MHC complexes at the cell surface. Cells were 
pulsed with graded concentrations of peptide, 
incubated for 1 h at 26˚C and incubated for an 
additional 2 h at 37˚C. After washing, cell surface 
expression of H-2Db was detected using the mAb 
28-14-8S which binds properly conformed Db-
peptide complexes on the cell surface, followed by 
secondary detection with a FITC-conjugated sheep 
anti-mouse Ig antibody (Chemicon/Millipore; cat. 
# A326; 1/500 dilution). Cells were analysed using 
a CyAn ADP flow cytometer (Beckman Coulter) 
in conjunction with FloJo software version 7.2.5.  
Purification of MHC-peptide complexes 
EBV transformed BLCLs, cytokine treated NIT-1 
cells (100 IU/mL IFNγ for 48 hours) and murine 
tissues (pooled thymus and spleens from 12-week-
old female NOD mice, n = 10) were harvested and 
snap frozen in liquid nitrogen. DC2.4 cells were 
infected with VACV-S510 at 5 PFU/cell and 
incubated for 4 hours before snap freezing. Frozen 
cell pellets or tissues were ground in a Retsch 
Mixer Mill MM 400  (2 min at 30 Hz) under 
cryogenic conditions, resuspended in a lysis buffer 
containing 0.5% IGEPAL  (Sigma), 50 mM Tris 
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pH 8, 150 mM NaCl and protease inhibitors  
(Complete Protease Inhibitor Cocktail t; Roche 
Molecular Biochemicals). For DC2.4, 1x108 
DC2.4s were disrupted by gentle resuspension in a 
total of 5 mls of lysis buffer without cryogenic 
milling. Lysates were incubated with rotation for 1 
h at 4 °C and cleared by centrifugation. MHC-
peptide complexes were immunoaffinity purified 
using specific monoclonal antibodies 28-14-8S  
(anti-H-2Db), SF1.1.10  (anti-H-2Kd), w632  (pan 
HLA class I), LB3.1  (anti-HLA-DR), SPV-L3  
(anti-HLA-DQ) or B721  (anti-HLA-DP) bound to 
protein A-Sepharose, as previously described 
(47,48). Bound complexes were eluted by 
acidification with 10 % acetic acid. The mixture of 
peptides and MHC protein chains was fractionated 
on a 4.6 mm internal diameter x 50 mm long 
reversed-phase C18 HPLC column (Chromolith 
Speed Rod, Merck) using an ÄKTAmicro™ 
HPLC system  (GE Healthcare) running on a 
mobile phase buffer A of 0.1 % trifluoroacetic 
acid  (TFA) and buffer B of 80 % acetonitrile/0.1 
% TFA and at a flow rate of 1 ml/min. 
Liquid chromatography-multiple reaction 
monitoring-mass spectrometry 
Following peptide elution, samples were 
concentrated and immediately analysed by mass 
spectrometry. An AB SCIEX QTRAP® 5500 
mass spectrometer was used for MRM detection, 
coupled on-line to a Tempo nano LC and nanoflex 
cHiPLC manifold  (Eksigent). 20 µl samples were 
injected and loaded onto a trap column  (200 µm x 
0.5 mm ChromXP C18-CL 3 µm 120 Å) at a flow 
rate of 10 µl/min in 98 % buffer A for 10 minutes. 
For on-line fractionation of samples onto the mass 
spectrometer, samples were eluted from the trap 
column and over a cHiPLC column  (75 µm x 15 
cm ChromXP C18-CL 3 µm 120 Å) at 300 nl/min 
under the following buffer B  (95 % acetonitrile, 
0.1 % formic acid in water) gradient conditions: 0-
3 min 2-10 % B, 3-33 min 10-40 % B, 33-36 min 
40-80 % B, 36-38 min hold at 80 % B, 38-39 min 
80-2 % B, followed by equilibration at 2 % B until 
the end of the run at 48 min. The QTRAP® 5500 
was operated in MRM mode in unit resolution for 
Q1 and Q3, coupled to an information-dependent 
acquisition  (IDA) criterion set to trigger an EPI 
scan  (10,000 Da/sec; rolling CE; unit resolution) 
following any MRM transition exceeding 500 
counts. Optimal MRM Q1>Q3 transition 
conditions were designed through analysis of 
synthetic peptides and are listed in Table 1. Data 
analysis was performed using Analyst v1.5.2  (AB 
SCIEX). 
Identification of MHC-bound peptides using LC-
MS/MS 
Peptide containing fractions were concentrated 
and loaded onto a microfluidic trap column packed 
with ChromXP C18-CL 3 m particles  (300 Å 
nominal pore size; equilibrated in 0.1% formic 
acid/5 % acetonitrile) at 5 μl/min using an 
Eksigent NanoUltra cHiPLC system. An analytical  
(15 cm x 75 m ChromXP C18-CL 3) 
microfluidic column was then switched in line and 
peptides separated using linear gradient elution of 
0-80 % acetonitrile over 90 min  (300 nl/min). 
Separated peptides were analysed using an AB 
SCIEX 5600 TripleTOF mass spectrometer 
equipped with a Nanospray III ion source and 
accumulating up to 30 MS/MS spectra per second. 
Data was analysed with ProteinPilotTM software 
and peptide identities determined subject to strict 
bioinformatic criteria that included the use of a 
decoy database to calculate the false discovery rate  
(FDR). A FDR cut-off of 5% was applied and the 
filtered dataset was further analysed manually to 
exclude redundant peptides and known 
contaminants. 
Intracellular cytokine staining and functional 
avidity 
Six to eight week old C57BL/6 mice were 
inoculated intranasally  (i.n.) with 4x104 PFU of 
JHMV. Mononuclear cells were harvested from 
the brains of acutely ill mice 7 days post infection 
(p.i.) and analyzed for expression of IFN-γ after 
peptide stimulation by an intracellular cytokine 
assay as previously described(49). Unless 
otherwise noted, peptides corresponding to S510 
or GSH-S510 epitope were used at a final 
concentration of 1 µM. GSH-510 peptide was 
generated by incubation of the native peptide in 
5mM reduced glutathione  (GSSG) in PBS for 4 
hrs followed by acidification and purification by 
RP-HPLC. For measurements of functional 
avidity, brain-derived cells were stimulated in the 
presence of antigen presenting cells  (CHB3 cells, 
B cell line, H-2Db, H-2Kb) and pulsed with 10-fold 
dilutions of the relevant peptide for 6 hr at 37 C 
in the presence of brefeldin A. Cells were analyzed 
for IFN- production. Cells were analyzed by flow 
cytometry using a FACSCalibur  (BD Biosciences, 
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Mountain View, CA). Data sets were analyzed 
using FlowJo software  (Tree Star, Inc, Ashland, 
OR). For each epitope-specific population, data 
were normalized to the maximum frequency of 
epitope-specific CD8+ T cells detected. Peptide 
concentration curves were fit to sigmoid 
concentration-response curves and used to 
calculate EC50 values. All antibodies and reagents 
were purchased from BD Pharmingen  (San Diego, 
CA).  
X-ray crystallographic studies 
The expression, purification and refolding of H-
2Db with murine -2 microglobulin and peptide 
was performed as described (39). Crystals of H-
2Db-GSH-S510 were grown at 21C in 0.1 M 
citrate pH 7.5, 28% PEG 3,350, 0.2M LiSO4, 
using a protein concentration of 3 mg/ml. Crystals 
were cryoprotected by equilibration against 
mother liquor containing 5% glycerol and flash 
frozen by placing in a nitrogen stream at 100K.  
The 2.8 Å dataset was collected on an in-house X-
ray generator and processed using HKL2000 (50). 
The structure was solved by molecular 
replacement in PHASER (51), using the protein 
coordinates of a previously solved H-2Db complex 
(PDBid: 1YN6) as a search model. The structure 
was initially subjected to simulated annealing and 
coordinate/atomic B-factor refinement in PHENIX 
(52), followed by iterative cycles of model 
building in COOT (53) and refinement in 
REFMAC (54) with TLS parameterisation. 
Structure validation was carried out using 
MOLPROBITY (55) and tools in the PHENIX 
package. Structure analysis was carried out using 
programs in CCP4i (56). A summary of data 
collection and refinement statistics is provided in 
Table 2. 
Despite being crystallised in the same condition, 
the S-glutathionylated H-2Db/S510 structure is 
characterised by a different, yet related, crystal 
symmetry to that observed for the non-S-
glutathionylated complex (PDBid: 2ZOK), which 
translates into small variations in the packing 
environment of individual pMHC molecules. 
These differences were taken into account when 
comparing the two structures. Two loop regions of 
the α1/α2 domain, in particular, which are 
involved in crystal contacts  (G16-E19 & G104-
D106) and display large conformational 
differences between the two structures were 
excluded from rmsd calculations. The α1/α2 
domain of the glutathionylated structure 
superimposes with individual pMHC copies of 
2ZOK with an average root mean square deviation 
(rmsd) of 0.28 Å for CA atoms and 0.92 Å for all 
atoms. The coordinates of the H-2Db- GSH-S510 




Modification of cysteine residues is common in T 
cell epitopes 
Due to technical challenges of working with 
cysteine-containing peptides, their importance in 
immunity remains under appreciated. To address 
this, we generated a large dataset of peptide 
sequences identified by mass spectrometry from 
immunoaffinity purified MHC class I and class II 
molecules that consists of over 70,000 high 
confidence peptide identities. A subset of these 
peptides arises from cells expected to be 
undergoing some degree of oxidative stress due to 
transformation (57) or cytokine exposure (22, 28, 
58,59). These peptides were isolated from a panel 
of EBV-transformed human B lymphoblastoid 
cells (BLCLs) expressing a variety of MHC alleles 
(12 different class I and 10 different class II 
alleles), murine NIT-1 cells (a pancreatic β cell 
line which is highly sensitive to IFN-γ treatment 
that expresses H-2Kd and H-2Db) and various 
murine tissues (see Table 3 for a list of cell lines 
and alleles). Global peptide repertoires were 
assessed by eluting peptides from these cells and 
analysis by tandem mass spectrometry, with 
epitope sequences determined from spectra by the 
Protein Pilot algorithm (60). Within this dataset, 
numerous cysteine-containing peptides were 
identified (Figure 1, Supplemental Table 1).  The 
frequency of cysteine-containing epitopes was 
influenced by the immunogenetics of the cell line 
with between 1-15% of class I restricted ligands 
and 3-28% of class II ligands found to contain at 
least one cysteine residue (Figure 1A). The higher 
percentage of cysteine-containing class II peptides 
was anticipated given their increased average 
length. The proportion of these ligands that 
contained a modified cysteine residue also varied 
with 25% of class I and 18% of class II ligands, on 
average, having a modified cysteine residue  
(Figure 1B). A high proportion contained 
modifications that were enzyme-mediated which 
are anticipated to occur in vivo. For instance, S-
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glutathionylation was found in a proportion of 
epitopes (Figure 1C, Supplemental Table 1) and 
was present at between 30-50% of the cysteine-
containing epitopes that were presented in 
modified form (Figure 1D). Many of these 
peptides were derived from proteins that are 
known physiological targets of S-
glutathionylation, such as ubiquitin ligases (61) 
and actin (62).  
 
Viral infection creates an environment for viral 
antigen modification 
The functional consequences of Cys-modification 
in MHC epitopes are ideally studied from the 
starting point of Cys-containing peptides that are 
known to induce strong T cell responses. A well-
characterized example is that of the 
immunodominant murine H-2Db-restricted epitope 
CSLWNGPHL, spanning residues 510-518 of the 
JHMV spike glycoprotein  (epitope S510) (39-
41,63).  Infection with JHMV results in an acute, 
fatal encephalitis or a chronic demyelinating 
disease, depending on the experimental protocol 
(63,64). This epitope is prone to oxidation in vitro, 
necessitating the use of a variant of S510 (bearing 
a Cys to aminobutyric acid (Abu) substitution at 
position 1) in functional and structural studies 
(39). Given that viral infection can induce cellular 
oxidative stress (20-27), we initially examined the 
redox state of JHMV-infected brains to determine 
whether the infected brain milieu would favour 
cysteine modification with oxidised glutathione. 
GSH and GSSG levels were assayed in brains 
harvested from either naive mice or mice at day 7 
post intranasal infection with JHMV (Figure 2). 
Infected mice were found to have significantly 
reduced ratios of reduced (GSH) to oxidised 
(GSSG) glutathione compared to uninfected 
controls, suggesting that this is an environment 
that is conducive for cysteine modification with 
oxidized glutathione. Therefore we next 
investigated whether the S510 epitope was S-
glutathionylated during infection using an in vitro 
system whereby DC2.4 cells (H-2b-restricted) 
were infected with a vaccinia virus (VACV) 
expressing the S510 epitope (VACV-S510) using 
a sensitive targeted mass spectrometry approach 
(multiple reaction monitoring, MRM) (48). This 
approach was chosen to generate enough material 
for the analysis since only a small number of APC 
are infected in the brain and VACV-S510 
reproduces aspects of the infection in mice (40) 
with ~4 % (Figure 3A) of splenic CD8+ T cells 
labelled with a H-2Db/S510-specific tetramer, a 
percentage similar to that detected after 
intraperitoneal infection with JHMV (65).  
Initially the MRM methodology was validated for 
the detection of both native S510 and modified 
GSH-S510 by exogenously loading H-2b+ve 
DC2.4 cells with synthetic S510 or GSH-S510 
(typically with an LOD of 500 amole) and 
incubating cells for 1 hour followed by extensive 
washing to remove unbound peptide. H-2Db-
peptide complexes were immunoprecipitated and 
bound peptides eluted using mild acid. Subsequent 
LC-MRM-MS analysis confirmed that both forms 
of S510 could be detected from their respective 
samples (Figure 3B), thus establishing the 
methodology for examining virus-infected 
samples. Under these conditions a small 
proportion of the native peptide was modified by 
GSH reflecting endogenous S-glutathionylation. 
These analyses also suggest that once modified, 
GSH-S510 was stable.  
Analysis of peptides eluted from DC2.4 cells at 4 
hours p.i. by targeted LC-MRM-MS revealed the 
presence of significant quantities of both native 
S510 and modified GSH-S510 in roughly 50:1 
proportion (Figure 3C). Further confirmation for 
the presence of these two peptide species was 
achieved by an MRM-triggered MS/MS 
sequencing scan (Figure 3D), where the MS/MS 
spectra obtained for the endogenously-processed 
peptides was compared to that obtained for 
synthetic S510 and GSH-S510.  
 
GSH-S510 is only recognized by a proportion of 
brain-derived CD8 T cells 
Following confirmation that VACV-S510 
infection leads to native and modified S510 
epitope presentation in vitro, and given that T cell 
responses to S510 can be generated by the same 
virus in vivo, we reasoned that JHMV infection 
would indeed lead to presentation of GSH-S510. 
Therefore, we determined whether CD8+ T cells in 
the brains of JHMV-infected mice recognised the 
H-2Db-GSH-S510 epitope, and in doing so 
assessed what impact S-glutathionylation of S510 
had upon T cell recognition. We observed that a 
similar percentage of CD8+ T cells produced IFN- 
upon direct ex vivo stimulation with saturating 
concentrations of either GSH-S510 or S510 
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peptide (Figure 4A). The response of CD8+ T cells 
to stimulation with saturating concentrations of 
peptide does not reflect the responsiveness  
(functional avidity) of the cells to physiological 
levels of presented peptide. Therefore, we 
determined the responsiveness of the brain-derived 
CD8+ T cells to titrated amounts of GSH-S510 or 
S510 peptide by measuring IFN- production upon 
stimulation and calculating the concentration of 
each peptide needed to reach a half maximum 
response  (EC50) (Figure 4B). GSH-S510 peptide 
was less potent than S510 peptide in inducing 
IFN- responses (EC50: 1.3x10-10 M vs 4.6x10-10 
M, respectively) (Figure 4B), suggesting that S-
glutathionylation of S510 moderately reduced 
CD8+ T cell recognition.    
Since it is possible that the JHMV-specific CD8+ 
T cell response consisted of cells specific to S510, 
GSH-S510, or dually specific to both forms of 
S510, we examined whether CD8+ T cells were 
composed of discrete populations by co-staining 
cells with H-2Db/GSH-S510 and H-2Db/S510 
tetramers.  Initially we stained CNS leukocytes 
isolated from JHMV-infected brains with APC- or 
PE-conjugated H-2Db tetramers loaded with either 
GSH-S510 or S510 peptide, respectively. On 
average, 48% of the CD8+ T cells present in the 
brain labelled with H-2Db/S510 tetramer, while 
only 36% stained with H-2Db/GSH-S510 tetramer 
again suggesting that S-glutathionylation of S510 
diminished CD8+ T cell recognition (Figure 
4C,D). Moreover, when CD8+ T cells were co-
stained with the tetramers, approximately 40% of 
H-2Db/S510 tetramer+ cells were not labelled with 
H-2Db/GSH-S510 tetramer, indicating that a 
considerable fraction of the cells recognize only 
the native form of S510. Virtually no cells were 
labelled solely with the H-Db/GSH-S510 tetramer 
(Figure 4C). Notably, there was also no distinct 
population of cells labelled with H-2Db/S510 
tetramer alone, suggesting that S-glutathionylation 
did not completely abrogate recognition by S510-
specific CD8 T cells. Rather the modification 
variably affected H-2Db/S510 interaction with a 
heterogeneous population of S510-specific CD8 T 
cells. This incomplete loss of binding after S-
glutathionylation may also explain the apparently 
discordant results observed in Figures 4A and C, 
since the saturating amounts of peptide used in 
Figure 4A could compensate for diminished H-
2Db/S510/TCR avidity, despite both peptides 
exhibiting equivalent binding to H-2Db (Figure 
4E). Differences between numbers of cells 
detected by MHCI/peptide binding and IFN- 
expression after peptide stimulation have been 
observed in other settings. For example, the 
subdominant CD8 T cell epitope recognized in B6 
mice (S598, spanning residues 598-605 of the S 
protein) elicits a low functional avidity response 
(39,66,67) that is detected by IFN- expression 
after peptide stimulation. However, the 
corresponding H-2Kb/S598 is able to detect only a 
minor fraction of these cells (65). 
 
The structure of GSH-S510 bound to H-2Db 
To evaluate the structural consequences of the 
presentation of glutathionylated S510, the 
structure of the H-2Db/GSH-S510 binary complex 
was determined to 2.8 Å resolution (see Table 2 
for data collection and refinement statistics). 
Initial refinement revealed clear unbiased density 
for the peptide with a covalent modification at P1. 
In complex with H-2Db, the GSH-S510 peptide 
adopts an extended conformation equivalent to 
that observed for the native peptide complex (PDB 
ID, 2ZOK) (39), with a kink about the proline at 
position 7. Briefly, the side chains of pN5 and pL9 
point down towards the floor of the cleft, while 
those of pC1, pW4, pP7 and pH8 point out of the 
cleft, and those of pS2 and pL3 are directed 
towards the α1 and α2 helices, respectively.  The 
side chains of pW4, pP7 and pH8 are highly 
solvent exposed and therefore in a position to play 
important roles in TCR recognition. 
Intramolecular contacts between the peptide side 
chains of pL3 and pN5 are consistent with a Type 
III constrained conformation(68) about the 
prominent TCR contact residue pW4(39). The 
GSH molecule is covalently linked to pC1 via a 
disulfide bond and extends prominently out of the 
cleft with its backbone lying roughly parallel to 
that of the peptide, but with its N- and C-termini 
adopting the opposite orientation to the peptide 
termini (Figure 5A). In this position GSH masks 
pC1-pL3 of the peptide and dominates the 
landscape of the N-terminal region of the complex. 
Anchoring of the GSH-S510 peptide to the cleft of 
H-2Db is mediated primarily by pC1, pS2, pN5 
and pL9 (see Table 4), which in addition to 
multiple Van der Waals contacts also form a 
number of hydrogen bond interactions with the 
heavy chain (Table 4, Figure 5B). The glutathione 
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tripeptide forms multiple van der Waals contacts 
with the heavy chain of H-2Db, as well as with the 
peptide residues pCys1 and pTrp4. In addition, its 
C-terminal glycine residue forms hydrogen bond 
contacts with Arg-62 and Trp-167, while its N-
terminal carboxylate side chain is able to form a 
salt bridge with guanidinium group of Arg-62. 
The antigen binding cleft of H-2Db in the 
glutathionylated structure adopts a conformation 
that is highly conserved with respect to that 
observed in the non-glutathionylated S510 
complex (PDBid: 2ZOK) (39) and the α1/α2 
domain of the glutathionylated structure 
superimposes with individual pMHC copies of 
2ZOK with an average root mean square deviation 
(rmsd) of 0.28 Å for CA atoms. Moreover, in the 
two structures the CSLWNGPHL peptide adopts 
an equivalent conformation, with an average rmsd 
between copies of 0.51 Å for all peptide atoms 
(Figure 5C, D). The only significant 
conformational difference in the peptide is 
observed at position Leu-3, the side chain of 
which displays maximum deviations of up to 2.4 
Å. This large side chain movement appears to be 
the result of the glutathione modification, which 
through interactions with the side chain of pW4 
forces the peptide backbone down into the cleft. 
The conformational change in the side chain of 
pL3 prevents steric clashes with the heavy chain’s 
Ser-99. The GSH modification also directly 
induces side chain movements in the H-2Db 
residues Arg-62 and Glu-163 that are up to several 
Angstrom in magnitude (Figure 5D). 
In addition to these local conformational changes 
in the pMHC, the glutathione modification caps 
the N-terminal region of the cleft, creating a TCR 
epitope that is unique to that observed in the native 
H-2Db/S510 structure, both in terms of shape and 
electrostatic properties. Despite this prominent 
structural change not all T cell recognition of the 
H-2Db/GSH-S510 was perturbed, with 60% of 
native epitope specific T cells capable of cross-
reacting as assessed by tetramer binding (Figure 
4D) reflecting the predominantly central focus of 
anti-S510 TcRs (39,41). The remaining 40% of 
CTLs presumably have a more N-terminal focus 
and their recognition was ablated, demonstrating 
that a previously unrecognized potential 
consequence of virus-induced stress is evasion of 
the T cell response.  
 
Discussion 
Cysteine residues are highly susceptible to 
oxidative modifications that are manifested 
through a variety of redox reactions and that are 
largely dependent on the nature of the antioxidant 
the protein encounters. For example, in the 
presence of ROS, mono-, di- and tri-oxidation to 
sulfenic, sulfinic and sulfonic acid, respectively, 
are prevalent. In the presence of reactive nitrogen 
species, S-nitrosylation or S-glutathionylation is 
predominant, with the latter arising from the 
detoxifying action of the abundant natural anti-
oxidant glutathione. In recent years it has become 
apparent that these modifications are not merely 
the footprint of oxidative stress but are also 
involved in the redox modulation of protein 
structure and function. Here we show that these 
dynamic modifications of cysteine residues are 
represented within the immunopeptidome 
presumably following processing of modified 
antigens. Thus, the presentation of cysteine-
containing peptides by MHC class I and class II 
molecules provides an opportunity to 
communicate the redox state of the cell to the 
immune system. By interrogating a large database 
of naturally processed and presented peptides 
bound to various MHC allotypes we demonstrated 
that the prevalence of cysteine-containing peptides 
varies between alleles but that on average largely 
reflects the cysteine usage within the proteome of 
host cells and pathogens. Importantly 20-30% of 
these peptides contained modified cysteine 
residues, a high proportion of which bore a 
specific enzyme catalysed modification: S-
glutathionylation. This represents the first large 
scale and systematic investigation of the cysteine-
containing immunopeptidome and reflects the 
chemical diversity achieved through oxidative 
modification of cysteine residues. 
Upon infection, a complex interplay of host-
mediated defence and virus-mediated counter 
mechanisms are elicited that dictate the outcome 
of the infection. Viral infection induces the 
unfolded protein response and oxidative stress. 
While dictating the productivity of viral 
replication, little is known about how such generic 
responses to viral-induced stress impact upon the 
ability of adaptive immunity to respond to virally 
infected cells. Depletion of antioxidants is a 
common theme during viral infection (30,33,34, 
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36,37,57) leading to an imbalance of cellular 
GSH:GSSG and under some circumstance an 
increase in protein S–glutathionylation (30). Here 
we demonstrate that during infection with JHMV a 
marked depletion in GSH is observed leading to 
conditions in the brain of infected mice conducive 
to S-glutathionylation of antigens. Modifications 
in GSH and GSSG resulting from increased 
oxidative stress have been previously reported in 
cells infected with hepatitis C virus (30,31) but to 
our knowledge, our study is the first to describe a 
difference in infected animals. Our results show 
that there is a statistically significant increase in 
the GSSG/GSH ratio in the brains of JHMV-
infected mice but additional work will be required 
to quantify the difference in this ratio that is 
predictive of a physiologically significant effect. 
However, our results suggest that the changes that 
we observe are biologically significant since the 
Cys-containing immunodominant T cell epitope, 
S510, derived from the spike glycoprotein  (S) of 
JHMV is presented in an unmodified  (S510) or 
glutathionylated  (S510-GSH) form in a redox 
sensitive manner. This indicates that presentation 
of this epitope to T cells informs the host of not 
only viral infection but also that of the redox state 
of the infected APC. Antigen pulsing experiments 
showed a requirement for intracellular processing 
of the antigen for this modification to occur, since 
addition of native S510 peptide to cells in culture 
did not lead to significant production of the GSH-
S510 epitope.  
T cells can be detected in infected mice that 
recognise the native form of this epitope or that 
cross-react towards both, suggesting a complex 
relationship between antigen presentation and 
oxidative stress in infected cells. We could not 
detect CD8 T cells that recognized only 
glutathionylated S510. One explanation for this is 
that glutathionylation occurs during peptide 
processing and loading onto the MHCI molecule. 
If epitope presentation occurred in JHMV-infected 
mice primarily via cross-presentation, cell stress 
and subsequent glutathionylation might occur to a 
lesser degree than in infected cells. The net result 
would be priming only to the native epitope, 
resulting in the lack of outgrowth of T cells 
responding only to GSH-S510.  
The cross-recognition of both S510 and GSH-
S510 by T cells can be appreciated from our 
structure and the previously reported bias in T cell 
recognition of the central regions of the S510 
epitope (39,41).  Approximately 15-35% of the T 
cell response, as assessed by MHC class I/peptide 
tetramer binding, is blunted by this modification; 
one would expect that modifications of cysteines 
that directly interacted with TCR would even more 
significantly impact recognition by native epitope-
specific cells, possibly contributing to evasion of 
the T cell response. CD8 T cell escape is common 
in JHMV and other viral infections, including 
those caused by HIV and hepatitis C virus (69,70) 
and generally involves mutations that inhibit 
epitope recognition or processing. Our data 
indicate that induction of the stress response, with 
subsequent post-translational modification of Cys 
residues may have the consequence of T cell 
escape. Our data indicate that induction of the 
stress response, with subsequent post-translational 
modification of Cys residues may have 
consequences for T cell escape. We speculate that 
this may be a common theme in viral infections 
and other pathologies such as tumours. If the 
redox state of a cell is altered such that Cys-
containing epitopes are modified, then cognate T 
cell responses may be diminished if there is 
insufficient cross-reactivity. Indeed, previous 
reports indicated that the oxidation state of Cys 
residues in candidate tumour peptide vaccines has 
influenced the anti-peptide CD4 and CD8 
responses. However, these effects vary from 
demonstrating reduced responses due to oxidation 
(71), to those showing recognition of both the 
monomeric or Cys-Cys dimerised epitope (72). In 
one study, Campos-Perez et al. argued that the use 
of DNA vaccines circumvented the concerns over 
spontaneous modification of synthetic epitopes, 
with any PTMs mirroring those that would be 
found on the endogenous tumour epitope (73). 
T cell epitopes bearing other cysteine 
modifications have been reported (74,75) yet the 
mechanism leading to their generation has 
remained elusive. Cysteinylation of T cell epitopes 
has been documented (18,75-77); however its 
precise biological role is uncertain with the 
possibility that oxidised cysteine, present in cell 
culture media results in this modification. Unlike 
cysteinylation, S-glutathionylation is a common 
modification of cysteine thiols in response to 
oxidative stress.  
In summary, we have mapped the subset of the 
immunopeptidome that contains redox sensitive 
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cysteine residues and show that a high proportion 
of cysteine containing peptides are oxidatively 
modified. The extent to which cysteine containing 
peptides are selected for presentation and the 
extent to which they bear modifications is allele 
dependent. The prevalence and chemical diversity 
of this subset of MHC ligands reiterates the 
importance of this often neglected class of 
peptides in immunity. In addition, we demonstrate 
that viral infection modulates the redox balance 
and skews the GSH:GSSG ratio promoting S-
glutathionylation, an observation consistent with 
other infectious systems.  This represents an 
effective mechanism for the cell to communicate 
oxidative stress to the immune system and to 
impact the host-virus axis. Consequent modulation 
of antigen presentation may have important 
implications for not only anti-viral immunity and 
vaccine development but also immunity to other 
pathogens that provoke stress responses and to 
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Figure 1 – Identification of cysteine-containing peptides in the immunopeptidome  
A) Proportion of cysteine-containing epitopes isolated and identified from a panel of B-
lymphoblastoid cell lines, NIT-1 cells and murine tissues. A large dataset of peptide sequences  
(over 70,000 high confidence peptide identities) were identified from immunoaffinity purified 
MHC class I and class II molecules. A subset of these peptides originated from cells undergoing 
some degree of oxidative stress induced by transformation or cytokine exposure. These peptides 
were isolated from a panel of EBV-transformed B lymphoblastoid cells  (BLCLs) spanning a 
variety of MHC alleles  (including International Histocompatibility Workshop consanguineous 
cell lines Jesthom, 9022 , 9013, 9031, 9087, and transfectants expressing defined HLA class I 
allotypes CIR B*27:05(47), CIR B*44:03(78), CIR B*57:01(79), CIR B*58:01(79), C1R 
B*57:03(79), CIR B*15:02(79);  721.221 A*01:01), murine NIT-1 cells, a pancreatic β cell line 
which is highly sensitive to IFN-γ treatment and various murine tissues from NOD mice (1,2). 
Global peptide repertoires were assessed by peptide elution and analysis by tandem mass 
spectrometry, with epitope sequences determined from spectra by the Protein Pilot algorithm. 
Each point represents different cell lines (see Supplemental Table 1). 
B) Proportion of cysteine containing epitopes bearing oxidative modifications. 
C) Proportion of modified epitopes with S-glutathionylation. 
D) A pie chart highlighting the proportion of cysteine containing epitopes bearing specific oxidative 
modifications. 
 
Figure 2 – Elevated levels of oxidised glutathione in infected mice brains.   
Reduced and oxidized glutathione levels and the GSG:GSSG ratio in naïve and JHMV-infected brain 
tissue at d7 p.i. Measurements were obtained as described in Materials and Methods. Data are from one 
experiment representative of three independent experiments (mean and s.e.m. with three mice per group).  
Figure 3 – Use of VACV-S510 as a surrogate for the study of S510 presentation and MRM-based 
detection of native and GSH-modified S510 presentation. 
A) Representative FACS plots of the frequencies of S510-specific T cells elicited in mice infected with 
recombinant VACV expressing epitope S510 (VACV-S510). Splenocytes were harvested from B6 mice 
intraperitoneally infected with 2x107 PFU of VACV-S510 at d7 p.i. and stained with a H-2Db/S510 
tetramer. Data from one of three mice analyzed are shown. 
B) Detection of S510 and GSH-S510 from DC2.4 cells exogenously loaded with the indicated peptides  
(1μM), or unpulsed as a negative control. Data show MRM traces (Q1>Q3 transitions as indicated) for 
both forms of the peptide. A small amount of native S510 was also detected in the GSH-S510-pulsed 
sample because the in vitro conversion of synthetic S510 to GSH-S510 is an incomplete reaction. C) 
Detection of S510 and GSH-S510 eluted from H-2Db-peptide complexes at 4 hours p.i. with VACV-
S510. MRM trace transitions are labeled as in (B). Data are from one of three independent experiments. 
D) Further confirmation of sequence and modification of S510 was obtained through MRM-triggered 
MS/MS sequencing scans (lower panels) compared to those from the corresponding synthetic peptide 
(upper panels). Representative sequencing ions are labeled. 
 
    Redox modulated antigen presentation 
17 
 
Figure 4 – Overlapping subsets of CD8+ T cells in the JHMV-infected brain recognize epitopes S510 
and GSH-S510. 
A) Representative FACS plots of the frequencies of brain-derived CD8+ T cells producing IFN- upon 
stimulation with either S510 or GSH-S510 peptide. Brain-derived mononuclear cells were isolated from 
the brains of mice infected with JHMV (4x104 PFU i.n.) at d7 p.i. Cells were stimulated ex vivo with 
either 1 M of S510 or GSH-S510 peptide and analyzed for IFN- production. B) Functional avidities of 
brain-derived CD8+ T cells specific for H-2Db/S510 or H-2Db/GSH-S510. Brain-derived cells were 
stimulated ex vivo with 10-fold dilutions of either S510 or GSH-S510 peptide and analyzed for 
intracellular IFN- production. Data were normalized to the maximum frequency of epitope-specific 
CD8+ T cells detected. Peptide concentrations curves were analyzed to fit to sigmoidal concentration-
response curves and used to calculate EC50 values. Data are from one experiment representative of three 
independent experiments  (mean and s.e.m. with four mice per group; ** p < 0.01). C) Representative 
FACS plots of the frequencies of brain-derived CD8+ T cells specific for H-2Db/S510 and H-2Db/GSH-
S510. CNS leukocytes isolated from JHMV-infected brains at d7 p.i. were incubated without tetramer  
(negative control) or stained with H-2Db/S510 tetramer, H-2Db/GSH-S510 tetramer, or co-stained with 
both tetramers. D) Frequencies of H-2Db/S510 tetramer-positive or H-2Db/GSH-S510 tetramer-positive 
CD8+ T cells isolated form JHMV-infected brains at d7 p.i.  (mean and s.e.m. with 8 mice per group; ** p 
< 0.01). E) RMA-S epitope stabilization assay examining S510 and GSH-S510 shows equivalent binding 
to H-2Db. 
 
Figure 5 – Overview of the structure of H-2Db/GSH-S510 and comparison against the native H-
2Db/S510 complex. 
A) The antigen binding cleft of H-2Db in complex with the GSH-CSLWNGPHL peptide. The heavy chain 
is drawn in cartoon format and coloured cyan. Glutathione and peptide residues are represented as orange 
and yellow sticks, respectively. B) Detail of the antigen-binding cleft, highlighting the contacts formed 
between H-2Db and the N-terminal half of the glutathionylated peptide. Heavy chain residues interacting 
with the ligand are shown in stick format. Hydrogen bonds are indicated by blue dashes. C) & D) 
Superposition of the structures of H-2Db in complex with the glutathionylated and non-glutathionylated 
forms of the CSLWNGPHL peptide. The superposition is based on main chain atoms of the peptide and 
residues 3-175 of the heavy chain of H-2Db. The large conformational changes displayed by the peptide 
residue Leu-3 and H-2Db residues Arg-62 and Glu-163 can be accounted for in terms of the glutathione 
modification. For clarity, the α2 helix has been rendered in semi-transparent mode in panel (A) and 
removed in panel  (C). In all panels the ligand residues are labelled in italics. 
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Table 1– MRM transitions for the detection of S510 and GSH-S510 
 
Epitope Sequence Q1 (charge) Q3 (ion) Optimal CE 
S510 CSLWNGPHL 513.7 (+2) 723.4 (y6) 20 
537.3 (y5) 20 
423.2 (y4) 20 
GSH-S510 GSH-
CSLWNGPHL 
444.5 (+3) 723.4 (y6) 17 
609.2 (b3) 17 
537.3 (y5) 17 
423.2 (y4) 17 
 
  




Table 2 - H2Db/GSH-S510 crystallographic statistics 
Data Collection & Processing 
Wavelength (Å) 1.5418 
Resolution limits (Å) a 16.00 – 2.80 (2.85 - 2.80) 
Space group P2221
Unit-cell parameters (Å) a = 75.699, b = 79.099, c = 85.933 
No. observations 46,607 
No. unique reflections a 11,701 (578) 
Mosaicity 1.1 
Completeness (%) a 87.9 (90.7) 
Rmerge  (%) a, b 12.3 (50.2) 
Rp.i.m.  (%) a, c 6.0 (25.4)
< I/(I) > a 10.5 (2.5) 
Multiplicity a                        4.0 (3.8) 
Refinement 
Resolution (Å) 15.9 – 2.8 
Working set reflections 10,373 
Test set reflections 1,176 
Data completeness (%) 87.9 
R-factor (%) d 20.8 
R-free (%) e 26.7 
 protein ligand solvent 
Number of atoms: 
li d
2,886 92 39 
Average atomic B-factors 
(Å2): 
60.6   53.1 37.1 
rmsd bonds (Å) 0.008 
rmsd angles (°) 1.127 
Ramachandran statistics (%): 
           - favoured 




a Values in parentheses refer to the highest resolution bin. 
b Rmerge = (hkl) i | Ii(hkl) - <I(hkl)> | / (hkl) i <I(hkl)> where I is the observed intensity and  < 
I > is the average intensity of multiple observations from symmetry-related reflections. 
c Rp.i.m. = (hkl) [1/(N-1)]1/2 i | Ii(hkl) - <I(hkl)> | / (hkl) i <I(hkl)> where N is the redundancy 
of the hkl reflection. 
d Rfactor = (  | |Fo| - |Fc| | ) / (  |Fo| )  - for all data except as indicated in footnote d. 
e 10.0% of data were used for the Rfree calculation (see footnote d). 
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Table 3. DNA typing and serological profiles  (bold) of cell types used for peptide elution. 
Cell Line Class I Class II 
Jesthom  (BLCL) 
 
 
COX  (BLCL) 
 
 
BOLETH  (BLCL) 
 
 
SCHU  (BLCL) 
 
 












A*02:01, B*27:05, C*01:02 
 (A2, B27, Cw1) 
 
A*01:01, B*08:01, C*07:01 
 (A1, B8, Cw7) 
 
A*02:01,B*1501, C*03:04,  
 (A2, B62, Cw10) 
 
A*03:01, B*07:02, C*07:02 
 (A3, B7, Cw7) 
 
A*01:01, B*08:01, C*07:01 
 (A1, B8, Cw7) 
 
A*01:01  (A1) 
B*1502  (B75, Cw4*) 
B*2705  (B27, Cw4*) 
B*5701  (B57, Cw4*) 
B*5703  (B57, Cw4*) 
B*5801  (B58, Cw4*) 
B*4403  (B44, Cw4*) 
Kd Db 
Kd Db 
DRA*01:01, DRB1*01:01, DQA1*01:01, DQB1*05:01, 
DPA1*01, DPB1*04:01 
 
 (DR1, DQ5, DP4) 
DRA*01:02, DRB1*03:01, DRB3*01:01, DQA1*05:01, 
DQB1*02:01, DPA1*01, DPB1*03:01 
 (DR3, DR52, DQ2, DP3) 
DRA1*01:01, DRB1*04:01, DRB4*01:03, 
DQA1*03:01, DQB1*03:02, DPA1*01:03, DPB1*04:01 
 (DR4, DR53, DQ8, DP4) 
DRA*01:02, DRB1*15:01, DRB5*01:01, DQA1*01:02, 
DQB1*06:02, DPA1*01, DPB1*04:02 
 (DR15, DR51, DQ6, DP4) 
DRA*01:02, DRB1*03:01, DRB3*01:01, DQA1*05:01, 
DQB1*02:01, DPA1*01, DPB1*03:01/04:01 










* C1R cells express low levels of Cw4. BLCL, B lymphoblastoid cell line. 
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Table 4. Ligand contacts in the H2Db/GSH-S510 binary structure 
H2Db/GSH-CSLWNGPHL 
Ligand Residue Interaction  Contacta, b
GSH VDWc C1, W4, R62, E63, K66, E163, W167 
GSHN3, O32,  HBd R62N2, W167N1 
GSHO11, O12 SBe R62N1
GSHS2 SSf C1S 
   
Cys1 VDW GSH, M5, Y7, E63, K66, Y159, E163, W167, Y171 
Cys1N, O HB Y7O, Y159O, Y171O 
Cys1S HB K66N
Cys1S SS GSHS2 
   
Ser2 VDW Y7, Y45, E63, K66, Y159 
Ser2N, O HB E63O1, K66N
Ser2O HB E63O1, K66N
   
Leu3 VDW N5, Q70, Q97, S99, L114, Y156, Y159,  
   
Trp4 VDW GSH, Q65, K66, G69, Q70, H155 
Trp4O HB H155N2 
   
Asn5 VDW L3, Q70, W73, Q97, F116, Y156 
Asn5N HB Q70O1 
Asn5O1, N2 HB Q97O1, N2 
   
Gly6 VDW W73, Y156 
Gly6N, O HB W73N1, Y156O 
   
Pro7 VDW W73, W147, S150, A152 
Pro7O HB W73N1 
Pro7O Smg Y156O 
   
His8 VDW W73, V76, S77, K146, W147 
His8O HB K146N, W147N1 
His8N1 Sm N80N2, K146N 
   
Leu9 VDW W73, S77, N80, L81, Y84, L95, Y123, T143, K146, 
W147 
Leu9N, O, OXT HB, SB S77O, N80N2, Y84O, T143O1, K146N 
a Atomic contacts determined using the CCP4i implementation of CONTACT and a cutoff of 4.0 Å. b Selected 
contacts between ligand residues are marked in italics. c VDW – Van der Waals’ interactions, defined as non-
hydrogen bond contact distances of 4.0 Å or less. d HB – Hydrogen bonds, defined as contact distances of 3.5 Å or 
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less between suitable atoms at appropriate angles. e SB – Ionic interactions, defined as contact distances of 4.0 Å or 
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